Aprea Therapeutics Inc./$APRE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Ticker
$APRE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
8
ISIN
US03836J2015
Website
APRE Metrics
BasicAdvanced
$9.7M
-
-$2.36
1.64
-
Price and volume
Market cap
$9.7M
Beta
1.64
52-week high
$2.79
52-week low
$1.41
Average daily volume
47K
Financial strength
Current ratio
5.901
Quick ratio
5.735
Profitability
EBITDA (TTM)
-15.234
Gross margin (TTM)
-697.70%
Net profit margin (TTM)
-1,096.27%
Operating margin (TTM)
-1,187.67%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-35.70%
Return on equity (TTM)
-59.80%
Valuation
Price to revenue (TTM)
8.13
Price to book
0.62
Price to tangible book (TTM)
0.62
Price to free cash flow (TTM)
-0.788
Free cash flow yield (TTM)
-126.97%
Free cash flow per share (TTM)
-222.52%
Growth
Revenue change (TTM)
33.27%
Earnings per share change (TTM)
-28.42%
3-year earnings per share growth (CAGR)
-58.35%
APRE News
AllArticlesVideos
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
GlobeNewsWire·2 days ago
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
GlobeNewsWire·1 month ago
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aprea Therapeutics Inc. stock?
Aprea Therapeutics Inc. (APRE) has a market cap of $9.7M as of June 27, 2025.
What is the P/E ratio for Aprea Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Aprea Therapeutics Inc. (APRE) stock is 0 as of June 27, 2025.
Does Aprea Therapeutics Inc. stock pay dividends?
No, Aprea Therapeutics Inc. (APRE) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Aprea Therapeutics Inc. dividend payment date?
Aprea Therapeutics Inc. (APRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Aprea Therapeutics Inc.?
Aprea Therapeutics Inc. (APRE) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.